The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
Items 401–500 of 883
Gene Therapy and Genome Editing
Boulad, F., Mansilla‐Soto, J., Cabriolu, A., Rivière, I., & Sadelain, M. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.007 · Cited by 24
Functional Genomic Characterization of Cancer GenomesPreprint
Howard, T. P., Vázquez, F., Tsherniak, A., Hong, A. L., Rinne, M. L., Aguirre, A. J., Boehm, J. S., & Hahn, W. C. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031070 · Cited by 24
Saeed, K., Ayub, F., Durrani, M. A., & Mujahid, M. (2025) · The Microbe · doi:10.1016/j.microb.2025.100344 · Cited by 26
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia
Frangoul, H., Hanna, R., Walters, M. C., Kao, R. L., Carroll, C., McManus, M. P., Chang, K., Jaskolka, M. C., Kim, K., Yu, Q., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2501277 · Cited by 23
Functional genomic approaches to elucidate the role of enhancers during development
Ryan, G. E., & Farley, E. K. (2019) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1467 · Cited by 22
Fetal Hemoglobin Regulation in Beta-Thalassemia
Lu, H. Y., Orkin, S. H., & Sankaran, V. G. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.002 · Cited by 28
Self-citationCheng, J., Roden, C., Pan, W. Q., Zhu, S., Eastman, A. E., Pan, X., Jiang, T., Kluger, Y., Weissman, S. M., Guo, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11178 · Cited by 23
Rapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies
Loucari, C. C., Patsali, P., van Dijk, T. B., Stephanou, C., Papasavva, P. L., Zanti, M., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., et al. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.190 · Cited by 23
Self-citationAcceleration of cancer science with genome editing and related technologies
Sakuma, T., & Yamamoto, T. (2018) · Cancer Science · doi:10.1111/cas.13832 · Cited by 24
Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis
Nandakumar, S. K., McFarland, S., Mateyka, L. M., Lareau, C. A., Ulirsch, J. C., Ludwig, L. S., Agarwal, G., Engreitz, J., Przychodzen, B. P., McConkey, M. E., et al. (2019) · eLife · doi:10.7554/elife.44080 · Cited by 21
CORALINA: a universal method for the generation of gRNA libraries for CRISPR-based screening
Köferle, A., Worf, K., Breunig, C., Baumann, V., Herrero, J., Wiesbeck, M. F., Hutter, L. H., Götz, M., Fuchs, C., Beck, S., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-3268-z · Cited by 20
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Lyu, J., Liu, Y., Gong, L., Chen, M., Madanat, Y. F., Zhang, Y., Cai, F., Gu, Z., Cao, H., Kaphle, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1661 · Cited by 23
Barbosa, I. A. M., Gopalakrishnan, R., Mercan, S., Mourikis, T. P., Martin, T., Wengert, S., Sheng, C., Ji, F., Lopes, R., Knehr, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39527-w · Cited by 23
Venkatesan, V., Srinivasan, S., Babu, P., & Thangavel, S. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-20 · Cited by 22
CRISPR/CAS9, the king of genome editing tools
Банников, А. В., & Лавров, А. В. (2017) · Molecular Biology · doi:10.1134/s0026893317040033 · Cited by 22
Lessard, S., Rimmelé, P., Ling, H., Moran, K., Vieira, B. F., Lin, Y.-D., Rajani, G. M., Hong, V., Reik, A., Boismenu, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74716-7 · Cited by 23
Demirci, S., Zeng, J., Palchaudhuri, R., Wu, C., Abraham, D. M., Hayal, T. B., Essawi, K., Nguyen, M. A., Stasula, U., Chu, R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.014 · Cited by 24
Self-citationThe Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease
Desine, S., Hollister, B. M., Abdallah, K. E., Persaud, A., Hull, S. C., & Bonham, V. L. (2020) · AJOB Empirical Bioethics · doi:10.1080/23294515.2020.1818876 · Cited by 23
Asano, Y., Yamashita, K., Hasegawa, A., Ogasawara, T., Iriki, H., & Muramoto, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-89546-0 · Cited by 24
CRISPR-Based Approaches for the High-Throughput Characterization of Long Non-Coding RNAs
Hazan, J. M., & Bester, A. C. (2021) · Non-Coding RNA · doi:10.3390/ncrna7040079 · Cited by 22
Han, Y., Tan, X., Jin, T., Zhao, S., Li, H., Zhang, W., Kurita, R., Nakamura, Y., Liu, J., Li, D., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174788 · Cited by 21
Self-citationSuper enhancers as master gene regulators in the pathogenesis of hematologic malignancies
Debek, S. M., & Juszczyński, P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188697 · Cited by 23
Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
Thuret, I., Ruggeri, A., Angelucci, E., & Chabannon, C. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac007 · Cited by 23
What do polymorphisms tell us about the mechanisms of COPD?
Li, Y., Cho, M. H., & Zhou, X. (2017) · Clinical Science · doi:10.1042/cs20160718 · Cited by 20
Targeting leukemia-specific dependence on the de novo purine synthesis pathway
Yamauchi, T., Miyawaki, K., Semba, Y., Takahashi, M., Izumi, Y., Nogami, J., Nakao, F., Sugio, T., Sasaki, K., Pinello, L., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01369-0 · Cited by 21
Self-citationActivity-by-Contact model of enhancer specificity from thousands of CRISPR perturbationsPreprint
Fulco, C. P., Nasser, J., Jones, T. R., Munson, G., Bergman, D. T., Subramanian, V., Grossman, S. R., Anyoha, R., Patwardhan, T. A., Nguyen, T. H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/529990 · Cited by 21
Functional Assays to Screen and Dissect Genomic Hits
Musunuru, K., Bernstein, D., Cole, F. S., Khokha, M. K., Lee, F. S., Lin, S., McDonald, T. V., Moskowitz, I. P. G., Quertermous, T., Sankaran, V. G., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002178 · Cited by 20
Transcriptional enhancers: from prediction to functional assessment on a genome-wide scale
Tobias, I. C., Abatti, L. E., Moorthy, S. D., Mullany, S., Taylor, T., Khader, N., Filice, M., & Mitchell, J. A. (2020) · Genome · doi:10.1139/gen-2020-0104 · Cited by 25
Advances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 21
Massively parallel disruption of enhancers active in human neural stem cells
Geller, E. T., Noble, M. A., Morales, M., Gockley, J., Emera, D., Uebbing, S., Cotney, J. L., & Noonan, J. P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113693 · Cited by 23
Moiani, A., Letort, G., Lizot, S., Chalumeau, A., Foray, C., Félix, T., Clerre, D. L., Temburni, S., Hong, P. W.-P., Leduc, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49353-3 · Cited by 21
Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing
Clarissa, E. M., Karmacharya, M., Choi, H., Kumar, S., & Cho, Y. (2025) · Small · doi:10.1002/smll.202409353 · Cited by 23
Applications of CRISPR genome editing technology in drug target identification and validation
Lu, Q., Livi, G. P., Modha, S. S., Yusa, K., Macarrón, R., & Dow, D. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1317244 · Cited by 21
Smith, A. J. P., Deloukas, P., & Munroe, P. B. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00028.2018 · Cited by 21
Hu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 24
Kurita, R., Funato, K., ABE, T. K., Watanabe, Y., Shiba, M., Tadokoro, K., Nakamura, Y., Nagai, T., & Satake, M. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.10.005 · Cited by 20
Self-citationAgrawal, P., Heimbruch, K. E., & Rao, S. (2018) · Comprehensive physiology · doi:10.1002/cphy.c180028 · Cited by 27
CRISPR Double Cutting through the Labyrinthine Architecture of 3D Genomes
Huang, H., & Wu, Q. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.03.006 · Cited by 19
Deletion of transcription factor binding motifs using the CRISPR/spCas9 system in the β-globin LCR
Kim, Y. W., & Kim, A. (2017) · Bioscience Reports · doi:10.1042/bsr20170976 · Cited by 19
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 21
Parallel genetics of regulatory sequences using scalable genome editing in vivo
Froehlich, J. J., Uyar, B., Herzog, M., Theil, K., Glažar, P., Akalin, A., & Rajewsky, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108988 · Cited by 18
Dissecting Plant Gene Functions Using CRISPR Toolsets for Crop Improvement
Zhang, R., Li, B., Yang, Z.-G., Huang, J., Sun, W.-H., Bhanbhro, N., Liu, W., & Chen, K. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c01754 · Cited by 20
Brusson, M., Chalumeau, A., Martinucci, P., Romano, O., Félix, T., Poletti, V., Scaramuzza, S., Ramadier, S., Masson, C., Ferrari, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.012 · Cited by 23
CRISPR/Cas9 system and its applications in human hematopoietic cells
Hu, X. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.09.003 · Cited by 22
CRISPR/CAS9 - КОРОЛЬ ГЕНОМНОГО РЕДАКТИРОВАНИЯ, "Молекулярная биология"
Банников, А. В., & Лавров, А. В. (2017) · Molecular Biology · doi:10.7868/s0026898417040036 · Cited by 19
BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells
Li, J., Yongrong, L., & Shi, L. (2018) · Hemoglobin · doi:10.1080/03630269.2018.1515774 · Cited by 18
Ali, G., Tariq, M. A., Shahid, K., Ahmad, F. J., & Akram, J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0153-9 · Cited by 20
Çizmecioğlu, N. T., Huang, J., Keskin, E. G., Wang, X., Esen, İ., Chen, F., & Orkin, S. H. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015534 · Cited by 19
Self-citationA tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing
Zheng, G., Yin, M., Mehta, S., Chu, I.-T., Wang, S., Alshaye, A., Drainville, K., Buyanbat, A., Bienfait, F., Tenglin, K., et al. (2024) · Science · doi:10.1126/science.adp3025 · Cited by 21
Self-citationPlant Gene Regulation Using Multiplex CRISPR-dCas9 Artificial Transcription Factors
Lowder, L. G., Malzahn, A. A., & Qi, Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7315-6_12 · Cited by 18
SEC23A rescues SEC23B-deficient congenital dyserythropoietic anemia type II
King, R., Lin, Z., Balbin-Cuesta, G., Myers, G., Friedman, A. D., Zhu, G., McGee, B. M., Saunders, T. L., Kurita, R., Nakamura, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5293 · Cited by 20
Self-citationInternally inlaid SaCas9 base editors enable window specific base editing
Jiang, L., Long, J., Yang, Y., Zhou, L., Su, J., Qin, F., Tang, W., Tao, R. X., Chen, Q., & Yao, S. (2022) · Theranostics · doi:10.7150/thno.70869 · Cited by 18
Chen, H. V., Lorenzini, M. H., Lavalle, S. N., Sajeev, K., Fonseca, A., Fiaux, P. C., Sen, A., Luthra, I., Ho, A. J., Chen, A. R., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.03.008 · Cited by 15
Katta, V., O’Keefe, K., Li, Y., Mayuranathan, T., Lazzarotto, C. R., Wood, R. K., Levine, R. M., Powers, A., Mayberry, K. D., Manquen, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.022 · Cited by 20
Modeling Cancer in the CRISPR Era
Ventura, A., & Dow, L. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050455 · Cited by 18
CRISPR-based methods for high-throughput annotation of regulatory DNA
Klann, T. S., Black, J. B., & Gersbach, C. A. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.02.004 · Cited by 19
Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 20
Bagchi, A., Nath, A., Thamodaran, V., Ijee, S., Palani, D., Rajendiran, V., Venkatesan, V., Datari, P. V. R., Pai, A. A., Arthur, N. B. J., et al. (2021) · Cells · doi:10.3390/cells10030523 · Cited by 18
Self-citationGenetic and Epigenetic Therapies for β-Thalassaemia by Altering the Expression of α-Globin Gene
Mettananda, S. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.752278 · Cited by 19
Clinical application of base editing for treating β-thalassaemia
Lai, Y., Liu, R., Wang, L., Ma, X.-K., Li, Y., Yang, G., Shi, L., Guo, Y., Wei, Z., Zhou, X., et al. (2026) · Nature · doi:10.1038/s41586-026-10342-9 · Cited by 19
Mnika, K., Pule, G. D., Dandara, C., & Wonkam, A. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0105 · Cited by 18
Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease
Ramadier, S., Chalumeau, A., Félix, T., Othman, N., Aknoun, S., Casini, A., Maule, G., Masson, C., Cian, A. D., Frati, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.019 · Cited by 17
Venkatesan, V., Christopher, A. C., Rhiel, M., Azhagiri, M. K. K., Babu, P., Walavalkar, K., Saravanan, B., Andrieux, G., Rangaraj, S., Srinivasan, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.024 · Cited by 18
Self-citationLi, M., Sun, J., & Shi, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1220376 · Cited by 20
Alayoubi, A. M., Khawaji, Z. Y., Mohammed, M. A., & Mercier, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05457-2 · Cited by 24
Recent advances in globin research using genome‐wide association studies and gene editing
Orkin, S. H. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13001 · Cited by 17
Self-citationDeciphering Combinatorial Genetics
Wong, A. S. L., Choi, G. C. G., & Lu, T. K. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-034902 · Cited by 17
Gene Editing for Inherited Red Blood Cell Diseases
Bustamante, O. Q., Fañanas-Baquero, S., Dessy-Rodríguez, M., Ojeda-Pérez, I., & Segovia, J. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.848261 · Cited by 20
Targeting fetal hemoglobin expression to treat β hemoglobinopathies
Steinberg, M. H. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066519 · Cited by 16
Recent advances in animal cell technologies for industrial and medical applications
Horie, M., Yamano, N., Kawabe, Y., Kaneoka, H., Fujita, H., Nagamori, E., Iwai, R., Sato, Y., Kanie, K., Ohta, S., et al. (2022) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2022.03.005 · Cited by 18
Molecular basis of polycomb group protein-mediated fetal hemoglobin repression
Qin, K., Lan, X., Huang, P., Saari, M. S., Khandros, E., Keller, C. A., Giardine, B. M., Abdulmalik, O. Y., Shi, J., Hardison, R. C., et al. (2023) · Blood · doi:10.1182/blood.2022019578 · Cited by 18
Alda-Catalinas, C., Ibarra-Soria, X., Flouri, C., Gordillo, J. E., Cousminer, D. L., Hutchinson, A., Sun, B., Pembroke, W. G., Ullrich, S., Krejčí, A., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03176-z · Cited by 18
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 23
An evolving understanding of multiple causal variants underlying genetic association signals
Long, E., Williams, J., Zhang, H., & Choi, J. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.01.018 · Cited by 18
Treating hemoglobinopathies using gene-correction approaches: promises and challenges
Cottle, R. N., Lee, C. M., & Bao, G. (2016) · Human Genetics · doi:10.1007/s00439-016-1696-0 · Cited by 17
Gene therapy for hemoglobin disorders - a mini-review
Malik, P. (2016) · Journal of Rare Diseases Research & Treatment · doi:10.29245/2572-9411/2016/2.1028 · Cited by 16
In The Blood: Connecting Variant to Function In Human Hematopoiesis
Nandakumar, S. K., Liao, X., & Sankaran, V. G. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.05.006 · Cited by 18
Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency
Wessels, M. W., Cnossen, M. H., van Dijk, T. B., Gillemans, N., Schmidt, K. L. J., van Lom, K., Vinjamur, D. S., Coyne, S. M., Kurita, R., Nakamura, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003753 · Cited by 16
Self-citationDahlqvist, J., Fulco, C. P., Ray, J. P., Liechti, T., de Boer, C. G., Lieb, D., Eisenhaure, T., Engreitz, J., Roederer, M., & Hacohen, N. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab372 · Cited by 15
Partridge, E. C., Watkins, T. A., & Mendenhall, E. M. (2016) · BioEssays · doi:10.1002/bies.201600028 · Cited by 15
A CRISPR view of gene regulation
Banerjee, B., & Sherwood, R. I. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.016 · Cited by 17
The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 18
Self-citationMitochondrial Diseases: Molecular Pathogenesis and Therapeutic Advances
Mei, J., Ding, P., Gao, C., Zhou, J., Li, Z., Zhang, C., & Gao, J. (2025) · MedComm · doi:10.1002/mco2.70385 · Cited by 17
Glaser, L. V., Steiger, M., Fuchs, A., van Bömmel, A., Einfeldt, E., Chung, H., Vingron, M., & Meijsing, S. H. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1100 · Cited by 14
Huang, C., Li, Q., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2022-0029 · Cited by 20
Hong, D., Lin, H., Liu, L., Shu, M., Dai, J., Lu, F., Tong, M., & Huang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac508 · Cited by 15
Integrative dissection of gene regulatory elements at base resolution
Chen, Z., Javed, N. M., Moore, M. M., Wu, J., Sun, G., Vinyard, M. E., Collins, A., Pinello, L., Najm, F. J., & Bernstein, B. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100318 · Cited by 17
Self-citationThe Role of Bcl11 Transcription Factors in Neurodevelopmental Disorders
Seigfried, F. A., & Britsch, S. (2024) · Biology · doi:10.3390/biology13020126 · Cited by 16
BCL2L1 is associated with γ-globin gene expression
Dai, Y., Mohammed, E. S. E., Perez, J. N., Wilson, C. A., Liu, L. Y., White, M. R., Farrell, J. J., Chui, D. H. K., Paola Sebastiani, B., & Steinberg, M. H. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019032243 · Cited by 15
CRISPR-Cas9 gene editing causes alternative splicing of the targeting mRNA
Zhang, Q., Fu, Y., Thakur, C., Bi, Z., Wadgaonkar, P., Qiu, Y., Xu, L., Rice, M., Zhang, W., Almutairy, B. S., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.145 · Cited by 15
Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan
Yamaguchi, T., Uchida, E., Okada, T., Ozawa, K., Onodera, M., Kume, A., Shimada, T., Takahashi, S., Tani, K., Nasu, Y., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.156 · Cited by 16
Comprehensive Mapping of Key Regulatory Networks that Drive Oncogene Expression
Lin, L., Holmes, B. R., Shen, M. W., Kammeron, D., Geijsen, N., Gifford, D. K., & Sherwood, R. I. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108426 · Cited by 14
Gamage, U., Warnakulasuriya, K., Hansika, S., & Silva, G. N. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13010006 · Cited by 17
CRISPR/Cas9-Mediated Hitchhike Expression of Functional shRNAs at the Porcine miR-17-92 Cluster
Lu, C., Pang, D., Li, M., Yuan, H., Yu, T., Huang, P., Li, J., Chen, X., Jiao, H., Xie, Z., et al. (2019) · Cells · doi:10.3390/cells8020113 · Cited by 15
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
Self-citationIdentification of rheumatoid arthritis causal genes using functional genomics
Ding, J., & Orozco, G. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12753 · Cited by 14
Gene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 15
PASTMUS: mapping functional elements at single amino acid resolution in human cells
Zhang, X., Yue, D., Wang, Y., Zhou, Y., Liu, Y., Qiu, Y., Tian, F., Yu, Y. F., Zhou, Z. L., & Wei, W. (2019) · Genome biology · doi:10.1186/s13059-019-1897-7 · Cited by 13
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
